TARLATAMAB-DLLE NCT06814496 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2030-05-01

Primary-completion proxy

Executive view

NCT06814496 evaluates TARLATAMAB-DLLE in Olfactory Esthesioneuroblastoma. The disclosed sponsor is University of Arizona, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Percentage of participants experiencing dose limiting toxicities (DLT) attributed to radiation or combination of radiation and tarlatamab., assessed over Until radiographic or disease progression or up to 24 months, whichever is earlier..

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06814496 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Olfactory Esthesioneuroblastoma landscape. Drug & Asset MCP drug_fetch was queried for TARLATAMAB-DLLE, while Company & Deal Intelligence MCP organization_fetch was queried for University of Arizona.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06814496	TARLATAMAB-DLLE	Phase 1/2 / Recruiting	University of Arizona	United States	Percentage of participants experiencing dose limiting toxicities (DLT) attributed to radiation or combination of radiat… Until radiographic or disease progression or up to 24 months, whichev…	2030-05-01
NCT06824662	Quisinostat Hydrochloride	Early Phase 1 / Active, not recruiting	St. Joseph's Medical Center, Inc.	United States	Quisinostat Concentration in Tumor Tissue Phase 0 surgery	2026-07-15
NCT06816927	Nivolumab	Phase 2 / Recruiting	Duke University	United States, Australia	Assess the safety of concomitantly administering nivolumab, relatlimab, RT, and TMZ in MGMT methylated patients by moni… From date of registration up to 4 weeks	2029-06-01
NCT06815029	Fludeoxyglucose F-18	Phase 1 / Recruiting	City of Hope National Medical Center	United States	Dose-limiting toxicities (DLTs) Up to 28 days	2030-10-11
NCT06815432	GLYCAR T cell therapy(Baylor College of Medicine)	Phase 1 / Recruiting	Baylor College of Medicine	United States	Number of Patients with Dose Limiting Toxicity 4 weeks	2029-12-05

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06814496 is a Phase 1/2, recruiting study with not reported planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.

The primary endpoint is “Percentage of participants experiencing dose limiting toxicities (DLT) attributed to radiation or combination of radiation and tarlatamab.” over “Until radiographic or disease progression or up to 24 months, whichever is earlier..” The retrieved endpoint description is: The primary endpoint is safety, which will be measured by DLT using adverse events graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0) and ASTCT (CRS and ICANS). DLT will be defined as having 1) grade 3 - 5 non-hematologic adverse events (AEs) possibly, probably or definitely related to protocol treatment (radiation or combination of radiation and tarlatamab) by 8 weeks from start of radiation therapy; or 2) AEs possibly, probably, or definitely related to radiation or combination of radiation and tarlatamab leading to early termination of radiation or permanent discontinuation of….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Olfactory Esthesioneuroblastoma. These records do not establish direct evidence for NCT06814496 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

TARLATAMAB-DLLE is indexed as Bispecific T-cell Engager (BiTE) with CD3 x DLL3 biology and a global stage of Approved. The asset profile lists Amgen, Inc. as an originator or developer.

University of Arizona is indexed in an unreported country with the website http://www.arizona.edu. University of Arizona provides undergraduate, graduate, and professional education across more than 150 majors and programs. The record lists 42 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether TARLATAMAB-DLLE is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06814496
Protocol source: https://clinicaltrials.gov/study/NCT06814496
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

TARLATAMAB-DLLE in Olfactory Esthesioneuroblastoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Percentage of participants experiencing dose limiting toxicities (DLT) attributed to radiation or combination of radiation and tarlatamab. and 2030-05-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP